<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100978">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02096159</url>
  </required_header>
  <id_info>
    <org_study_id>LC/Uro-MF-01</org_study_id>
    <nct_id>NCT02096159</nct_id>
  </id_info>
  <brief_title>Prophylactic Antibiotics or Placebo After Hypospadias Repair</brief_title>
  <acronym>PROPHY</acronym>
  <official_title>Trimethoprim-sulfamethoxazole vs. Placebo After Hypospadias Repair: a Multicenter, Double-blind, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ann &amp; Robert H Lurie Children's Hospital of Chicago</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine whether routine use of prophylactic
      (preventive) antibiotics is beneficial or unnecessary after hypospadias repair.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants in this multicenter, double-blind study are randomized to receive
      trimethoprim-sulfamethoxazole or placebo for 10 days postoperatively. Short- and
      intermediate-term results will be published after participants complete 6 months and 5 years
      of follow-up, respectively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>postoperative infection</measure>
    <time_frame>up to 1 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>wound-healing complications</measure>
    <time_frame>up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>meatal stenosis; urethral stricture; urethrocutaneous fistula; dehiscence; urethral diverticulum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse drug reaction</measure>
    <time_frame>up to 14 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C. difficile colitis</measure>
    <time_frame>up to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">630</enrollment>
  <condition>Hypospadias</condition>
  <arm_group>
    <arm_group_label>Antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trimethoprim-sulfamethoxazole oral suspension, 4 mg/kg (0.5 mL/kg) twice daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo oral suspension, 0.5 mL/kg twice daily for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trimethoprim-sulfamethoxazole</intervention_name>
    <arm_group_label>Antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mid-to-distal shaft hypospadias

          -  single-stage hypospadias repair with circumcision

          -  length of urethral repair (urethroplasty) no greater than 20 mm

          -  placement of an open-drainage urethral stent at the time of hypospadias repair, with
             intended duration of stenting of 5-10 days post-operatively

        Exclusion Criteria:

          -  previous hypospadias or other penile surgery, including circumcision

          -  prior adverse/allergic reaction or other contraindication to
             trimethoprim-sulfamethoxazole

          -  cross-reactivity of an existing medication with trimethoprim-sulfamethoxazole

          -  HIV/AIDS, poorly controlled diabetes mellitus or other immunocompromising conditions

          -  use of antibiotics within seven days prior to hypospadias repair

          -  foreskin reconstruction at the time of hypospadias repair

          -  prescription of oral antibiotics other than Study Medication at the time of
             hypospadias repair
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Earl Y Cheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark A Faasse, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark A Faasse, MD</last_name>
    <phone>(312) 227-6743</phone>
    <email>mfaasse@luriechildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Theresa Meyer, MS, RN, CPN</last_name>
    <phone>(312) 227-6734</phone>
    <email>tmeyer@luriechildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ann &amp; Robert H Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark A Faasse, MD</last_name>
      <phone>312-227-6743</phone>
      <email>mfaasse@luriechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Theresa Meyer, MS, RN, CPN</last_name>
      <phone>(312) 227-6734</phone>
      <email>tmeyer@luriechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Earl Y Cheng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dennis B Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark A Faasse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Walid A Farhat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph M Gleason, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.prophystudy.info/</url>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 13, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</investigator_affiliation>
    <investigator_full_name>Earl Y Cheng, MD</investigator_full_name>
    <investigator_title>Head, Division of Urology</investigator_title>
  </responsible_party>
  <keyword>Hypospadias</keyword>
  <keyword>Anti-Bacterial Agents</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypospadias</mesh_term>
    <mesh_term>Epispadias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim-Sulfamethoxazole Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
